Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros
Ashraf
A
University of Maryland, Greenebaum Cancer Center, Baltimore, MD, 21201, USA. abadros@umm.edu
Gahres
Natalie
N
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone